معرفی
Talat Bessissow is an Associate Professor in the Department of Medicine at McGill University and an Investigator at the RI-MUHC (Montreal General Hospital site) under the Infectious Diseases and Immunity in Global Health Program. His work bridges clinical practice at the MUHC with academic research in gastroenterology.
Research Focus
Bessissow’s research centers on mucosal healing as a therapeutic target in Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis. He investigates predictors of disease relapse and optimizes endoscopic surveillance for neoplasia. His work integrates clinical trials, biologics, and advanced imaging techniques to improve patient outcomes.
Publications Overview
His recent studies focus on comparative efficacy of biologics (e.g., risankizumab, vedolizumab), endoscopic outcomes in Crohn’s disease, and patient-reported metrics in ulcerative colitis. These publications emphasize network meta-analyses, real-world data, and treatment optimization.
Collaborations
He collaborates with international teams across institutions like the RI-MUHC, McGill University, and global research groups in Europe and Asia, reflecting his expertise in global health and translational medicine.
